Alpha 2.0

» Articles » PMID: 35586286

Paclitaxel-coated Balloons Angioplasties for Extra-long Femoropopliteal Artery Atherosclerotic Lesions (> 30 cm):12 Months Outcomes from a Single Center

Overview

Overview

Journal J Interv Med

Specialty General Medicine

Date 2022 May 19

PMID 35586286

Authors

Authors

Tao Pan

Guodong Zhang

Zhen Liu

Tao Zhang

Cheng Li

Donghua Ji

Affiliations

Affiliations

Soon will be listed here.

Abstract

Objective: To evaluate the efficacy of paclitaxel-coated balloon (PCB) in the treatment of extra-long femoropopliteal artery atherosclerotic disease (>30 cm).

Materials And Methods: Forty-nine patients with extra-long femoropopliteal artery atherosclerotic disease were treated with PCB alone in a single center from July 2016 to May 2018. Primary patency and freedom from clinically driven target lesion revascularization (FF-CDTLR) rates during 12 months were analyzed retrospectively.

Results: All patients were followed up for 18.2 ± 7.5 months, and the mean treated lesion length was 34.9 ± 3.7 cm. The primary patency rates were 87.8% (43/49) and 71.4% (35/49) at 6 and 12 months, respectively. FF-CDTLR was 91.8% (45/49) and 77.6% (38/49) at 6 and 12 months, respectively. No mortality or amputation occurred in these patients during the follow-up period.

Conclusions: PCB has favorable clinical efficacy in patients with extra-long femoropopliteal artery atherosclerotic lesions.

References

1.

Tosaka A, Soga Y, Iida O, Ishihara T, Hirano K, Suzuki K . Classification and clinical impact of restenosis after femoropopliteal stenting. J Am Coll Cardiol. 2011; 59(1):16-23. DOI: 10.1016/j.jacc.2011.09.036. View

2.

Micari A, Cioppa A, Vadala G, Stabile E, Castriota F, Pantaleo P . A new paclitaxel-eluting balloon for angioplasty of femoropopliteal obstructions: acute and midterm results. EuroIntervention. 2011; 7 Suppl K:K77-82. DOI: 10.4244/EIJV7SKA14. View

3.

Scheinert D, Duda S, Zeller T, Krankenberg H, Ricke J, Bosiers M . The LEVANT I (Lutonix paclitaxel-coated balloon for the prevention of femoropopliteal restenosis) trial for femoropopliteal revascularization: first-in-human randomized trial of low-dose drug-coated balloon versus uncoated balloon angioplasty. JACC Cardiovasc Interv. 2014; 7(1):10-9. DOI: 10.1016/j.jcin.2013.05.022. View

4.

Tepe G, Schmitmeier S, Speck U, Schnorr B, Kelsch B, Scheller B . Advances on drug-coated balloons. J Cardiovasc Surg (Torino). 2010; 51(1):125-43. View

5.

Biondi-Zoccai G, Sangiorgi G, DAscenzo F, Zuffi A, Lotrionte M, Romagnoli E . Drug-eluting balloons for peripheral artery disease: a meta-analysis of 7 randomized clinical trials and 643 patients. Int J Cardiol. 2013; 168(1):570-1. DOI: 10.1016/j.ijcard.2013.01.247. View

6.

Davaine J, Azema L, Guyomarch B, Chaillou P, Costargent A, Patra P . One-year clinical outcome after primary stenting for Trans-Atlantic Inter-Society Consensus (TASC) C and D femoropopliteal lesions (the STELLA "STEnting Long de L'Artère fémorale superficielle" cohort). Eur J Vasc Endovasc Surg. 2012; 44(4):432-41. DOI: 10.1016/j.ejvs.2012.07.015. View

7.

Caradu C, Lakhlifi E, Colacchio E, Midy D, Berard X, Poirier M . Systematic review and updated meta-analysis of the use of drug-coated balloon angioplasty versus plain old balloon angioplasty for femoropopliteal arterial disease. J Vasc Surg. 2019; 70(3):981-995.e10. DOI: 10.1016/j.jvs.2019.01.080. View

8.

Bosiers M, Deloose K, Callaert J, Moreels N, Keirse K, Verbist J . Results of the Protégé EverFlex 200-mm-long nitinol stent (ev3) in TASC C and D femoropopliteal lesions. J Vasc Surg. 2011; 54(4):1042-50. DOI: 10.1016/j.jvs.2011.03.272. View

9.

Baril D, Chaer R, Rhee R, Makaroun M, Marone L . Endovascular interventions for TASC II D femoropopliteal lesions. J Vasc Surg. 2010; 51(6):1406-12. DOI: 10.1016/j.jvs.2010.01.062. View

10.

Tepe G, Zeller T, Albrecht T, Heller S, Schwarzwalder U, Beregi J . Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg. N Engl J Med. 2008; 358(7):689-99. DOI: 10.1056/NEJMoa0706356. View

11.

Armstrong E, Brodmann M, Deaton D, Gray W, Jaff M, Lichtenberg M . Dissections After Infrainguinal Percutaneous Transluminal Angioplasty: A Systematic Review and Current State of Clinical Evidence. J Endovasc Ther. 2019; 26(4):479-489. DOI: 10.1177/1526602819855396. View

12.

Rosenfield K, Jaff M, White C, Rocha-Singh K, Mena-Hurtado C, Metzger D . Trial of a Paclitaxel-Coated Balloon for Femoropopliteal Artery Disease. N Engl J Med. 2015; 373(2):145-53. DOI: 10.1056/NEJMoa1406235. View

13.

Tepe G, Laird J, Schneider P, Brodmann M, Krishnan P, Micari A . Drug-coated balloon versus standard percutaneous transluminal angioplasty for the treatment of superficial femoral and popliteal peripheral artery disease: 12-month results from the IN.PACT SFA randomized trial. Circulation. 2014; 131(5):495-502. PMC: 4323569. DOI: 10.1161/CIRCULATIONAHA.114.011004. View

14.

Garcia L, Jaff M, Metzger C, Sedillo G, Pershad A, Zidar F . Wire-Interwoven Nitinol Stent Outcome in the Superficial Femoral and Proximal Popliteal Arteries: Twelve-Month Results of the SUPERB Trial. Circ Cardiovasc Interv. 2015; 8(5). DOI: 10.1161/CIRCINTERVENTIONS.113.000937. View

15.

Tepe G, Gogebakan O, Redlich U, Tautenhahn J, Ricke J, Halloul Z . Angiographic and Clinical Outcomes After Treatment of Femoro-Popliteal Lesions with a Novel Paclitaxel-Matrix-Coated Balloon Catheter. Cardiovasc Intervent Radiol. 2017; 40(10):1535-1544. DOI: 10.1007/s00270-017-1713-2. View

16.

Schillinger M, Sabeti S, Dick P, Amighi J, Mlekusch W, Schlager O . Sustained benefit at 2 years of primary femoropopliteal stenting compared with balloon angioplasty with optional stenting. Circulation. 2007; 115(21):2745-9. DOI: 10.1161/CIRCULATIONAHA.107.688341. View

17.

Matsumura J, Yamanouchi D, Goldstein J, Pollock C, Bosiers M, Schultz G . The United States StuDy for EvalUating EndovasculaR TreAtments of Lesions in the Superficial Femoral Artery and Proximal Popliteal By usIng the Protégé EverfLex NitInol STent SYstem II (DURABILITY II). J Vasc Surg. 2013; 58(1):73-83.e1. DOI: 10.1016/j.jvs.2012.12.066. View

18.

Werk M, Langner S, Reinkensmeier B, Boettcher H, Tepe G, Dietz U . Inhibition of restenosis in femoropopliteal arteries: paclitaxel-coated versus uncoated balloon: femoral paclitaxel randomized pilot trial. Circulation. 2008; 118(13):1358-65. DOI: 10.1161/CIRCULATIONAHA.107.735985. View

19.

Thieme M, von Bilderling P, Paetzel C, Karnabatidis D, Delgado J, Lichtenberg M . The 24-Month Results of the Lutonix Global SFA Registry: Worldwide Experience With Lutonix Drug-Coated Balloon. JACC Cardiovasc Interv. 2017; 10(16):1682-1690. DOI: 10.1016/j.jcin.2017.04.041. View

20.

Gray W, Feiring A, Cioppi M, Hibbard R, Gray B, Khatib Y . S.M.A.R.T. self-expanding nitinol stent for the treatment of atherosclerotic lesions in the superficial femoral artery (STROLL): 1-year outcomes. J Vasc Interv Radiol. 2014; 26(1):21-8. DOI: 10.1016/j.jvir.2014.09.018. View